Society for Translational Oncology Fellows’ Forum (STOFF)

The Lansdowne, Leesburg, VA, USA

A significant component of the STOFF program is the in-person time faculty and fellows spend together for mentorship and discussion. Based on guidance from the co-chairs, feedback from the faculty, and the current pandemic circumstances, this year’s Forum, originally scheduled for January 27-29, has been postponed to Thursday, August 18 - Saturday, August 20, 2022.

Society for Translational Oncology Fellows' Forum (STOFF) is an intensive 3-day workshop that brings together fellows and junior faculty within 5 years of training completion from the leading medical, surgical, radiation, and pediatric oncology groups and subspecialty fellowships to educate these rising stars on issues around and barriers to successful translational cancer research. A distinguished faculty of prominent scientists, clinicians, ethicists, industry representatives, and biotech investors serve as mentors.

The cornerstones of STOFF are the faculty members who volunteer both their time and wealth of experience. Co-chaired by Keith Flaherty (Massachusetts General Hospital/Harvard Medical School), Stacey Berg (Baylor College of Medicine), and Ross Levine (Memorial Sloan Kettering Cancer Center), the STOFF faculty includes researchers and educators from the US FDA and several leading US cancer centers.

The workshop has received international acclaim for its focused, practical, and personal approach, including opportunities for networking with peers and mentoring from faculty. The broad-based curriculum covers a range of topics related to new drug development. Faculty lecture and lead discussions on preclinical and clinical evaluation, validation of targets and biomarkers, confirmation of mechanism of action and resistance in clinical trials, and racial and age-related disparities in clinical trials, and includes the mechanics of grant-writing and guidelines for good basic research.

Educating young oncologists in the field of clinical and translational research is an investment in the future and is likely to impact the quality of cancer patient care for years to come,” said Bruce A. Chabner (Massachusetts General Hospital/Harvard Medical School), who founded the course more than two decades ago. Since then, many of the 540+ alumni have earned significant acclaim in their careers and drug development success.